TNDMTandem Diabetes Care, Inc.
$16.12+28% 1Y
$16.12
$11.7952 weeks$28.26
The financials
Tandem Diabetes Care, Inc. by the numbers
Tandem Diabetes Care, Inc. (TNDM) reported revenue of $255M in Q2 2026 (quarter ended Jun 30, 2026), up 5.8% from the same quarter a year earlier. That came with a gross margin of 57% and net loss of $21M. For the full year FY2025, revenue was $1.01B (+7.9% year on year) and net income −$205M. Its largest product in Q2 2026 was Supplies And Other at $140M, 55% of the disclosed total, ahead of Pump at 45%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $255M | $241M | +5.8% |
| Gross profit | $145M | $126M | +15% |
| Operating income | −$14M | −$52M | n/a |
| Net income | −$21M | −$52M | n/a |
| Diluted EPS | −$0.31 | −$0.78 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Supplies And Other | $140M | 55% |
| Pump | $115M | 45% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $254.6M (+3.0%)
Supplies And Other grew +8.6% year on yearPump +2.5% year on year
Segment Latestquarter on quarteryear on year
- Supplies And Other$139.9M$139.9Mquarter on quarter +2.3%year on year +8.6%+2.3%+8.6%
- Pump$114.7M$114.7Mquarter on quarter +3.9%year on year +2.5%+3.9%+2.5%
On our screens:Most shorted stocks